An antibody-drug conjugate (ADC) that GSK licensed from China's Hansoh Pharma in a $1.7 billion deal last year has been given breakthrough status by the FDA. The coveted designation for GSK5764227 ...
Adcendo has tapped into the strong investor appetite for companies developing antibody-drug conjugates for cancer with an oversubscribed second round that raised $135 million. The Copenhagen, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback